Outcomes after double switching from originator Infliximab to biosimilar CT‐P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12‐month prospective cohort studyNoémie Trystram, Aurélien Amiot, Jenny Tannoury et al.|Alimentary Pharmacology & Therapeutics|2021Cited by 30